After nearly a decade of sky-high prices, generics have sent the price of the HIV prevention drug PrEP plummeting. What kept it so expensive for so long, and will the price drop help us finally eradicate HIV?Guests:Robin Feldman, Professor of Law, UC Hastings; Director of the Center for InnovationTahir Amin, Co-Executive Director, I-MAKOni Blackstock, MD, Primary care and HIV physicianTim Horn, Director of Health Care Access, National Alliance of State and Territorial AIDS DirectorsCraig Garthwaite, Director of Health Care, Kellogg School of Management, Northwestern Univ.Dig deeper into the research and tradeoffs of prescription drug pricing on our website: https://tradeoffs.org/2021/04/22/preventing-hiv-just-got-a-lot-cheaper-what-took-so-long/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios